Nanobiotix (NASDAQ:NBTX) Shares Down 4.7% - Here's What Happened

Key Points

• Nanobiotix shares fell 4.7% to about $39.73, with trading volume roughly 40% below the average session volume.
• Analyst sentiment remains mixed but leans positive: four analysts rate the stock a Buy, one a Hold and one a Sell. The consensus rating is “Moderate Buy,” with an average price target of $37.33.
• Institutional investors own 38.81% of Nanobiotix, while the clinical-stage biotech continues developing NBTXR3, a nanopharmaceutical designed to enhance radiotherapy, with programs spanning several cancer indications.

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report) shares were down 4.7% during trading on Thursday . The stock traded as low as $39.65 and last traded at $39.7250. Approximately 50,929 shares were traded during trading, a decline of 40% from the average session volume of 85,269 shares. The stock had previously closed at $41.67.

Analyst Ratings Changes

NBTX has been the topic of several research analyst reports. Leerink Partners boosted their price objective on Nanobiotix from $37.00 to $46.00 and gave the company an "outperform" rating in a report on Thursday, June 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nanobiotix in a research note on Friday, July 17th. Finally, HC Wainwright reissued a "buy" rating on shares of Nanobiotix in a research note on Monday, May 18th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Nanobiotix presently has an average rating of "Moderate Buy" and an average target price of $37.33.

Nanobiotix Stock Performance

The business has a 50-day moving average price of $39.55 and a two-hundred day moving average price of $36.52.

Institutional Investors Weigh In On Nanobiotix

Large investors have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in shares of Nanobiotix in the 4th quarter valued at about $390,000. Marshall Wace LLP purchased a new stake in shares of Nanobiotix during the fourth quarter worth approximately $220,000. Finally, Royal Bank of Canada raised its holdings in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company's stock valued at $61,000 after acquiring an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 38.81% of the company's stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company's lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source